Skip to main content
NCBI home page
Cell Transplantation logoLink to Cell Transplantation
. 2020 Jul 13;29:0963689720920815. doi: 10.1177/0963689720920815

The Inhibitory Effect of Carboplatin Injection on Human Neuroblastoma SK-N-SH

Jianfeng Xu 1,2,*, Zhiyong Liu 1,*, Yang Liu 2, Guiqiang Wu 2, Lingyong Zeng 2, Jianguo Xu 1,✉
PMCID: PMC7586261  PMID: 32659114

Abstract

The purpose of our study was to investigate the inhibitory effect of carboplatin injection on human neuroblastoma human neuroblastoma cell (SK-N-SH) cells and to clarify its action mechanism. In this study, human neuroblastoma SK-N-SH cells were divided into two groups. The treatment group was intervened by carboplatin injection (25 μM), while the control group was intervened by drug solvent. After treating separately for 24 and 72 h, the cells were collected, and western blot (WB) and real-time PCR were used to detect the expression of the proliferation marker protein (Ki67); cells grown on cover slips were prepared and immunocytochemistry (ICC) and hematoxylin–eosin (HE) staining were adopted to observe the protein expression of Ki67 and the morphological changes of the cells; clone formation assay was used to detect the clonality of each cell group. The cytotoxicity of carboplatin on SK-N-SH cell was checked by AlamarBlue viability test. Both WB and PCR results showed that after cells were injected with carboplatin for 24 and 72 h, the expression levels of both Ki67 gene and protein were decreased, and they had a significant difference from those of the control group. Carboplatin injection inhibited the expression of Ki67, and the inhibitory effect was particularly significant as the action time prolonged. ICC results showed that the protein expression of Ki67 in the treatment group was lower than that in the control group, and there was a significant difference in expression between them. As shown by HE results, the number of cell necrosis and apoptosis in the treatment group was significantly higher than that in the control group, while the results of clone formation assay showed that in the treatment group, after being injected with carboplatin, the proliferation ability of cells was inhibited, so the number of cells was significantly reduced compared with that of the control group. Carboplatin at the tested concentration displayed no cytotoxicity on SK-N-SH cell. The conclusions are that carboplatin injection can inhibit human neuroblastoma SK-N-SH cells, and the longer it acts on SK-N-SH cells, the more obvious the inhibitory effect would be.

Keywords: carboplatin injection, human neuroblastoma SK-N-SH, Ki67

Introduction

Neuroblastoma, as one of the most common malignant tumors in children, accounts for 8%–10% tumors in children. The incidence of infants aged below 2 suffering from neuroblastoma SK-N-SH is 50%, so it has a high mortality rate1,2. Neuroblastoma is a type of cancer developed from immature nerve cells of the body, which mostly originate from the sympathetic nerves of the chest and abdomen. The symptoms of this disease are abdominal distension, abdominal pain, vomiting, anorexia, weight loss, fatigue, and so on. Although there are currently many therapeutic schemes for neuroblastoma such as surgical resection, radiotherapy, and chemotherapy, the survival rate of children is still low, so it poses a serious threat to the health of infants3–8. It has been found that clinical drugs used for treating other tumors may play a role in the treatment of neuroblastoma.

Carboplatin injection used for clinical treatment has a good curative effect9 on some solid tumors including ovarian cancer, nonsmall cell lung cancer, and head–neck carcinoma. According to literature reports, carboplatin injection has a certain effect on other tumor cells10–14. In this study, a certain concentration of carboplatin injection was used to intervene with human neuroblastoma cells, and by detecting the expression of proliferation marker protein Ki67 as well as by testing the proliferation ability of cells through clone formation assay, it was found that carboplatin injection had a certain inhibitory effect on neuroblastoma15–19. It laid a foundation for the follow-up mechanism study and a theoretical basis for the future cure of neuroblastoma.

Materials and Methods

Ethical Approval

The study was approved by the Institutional Ethics Committee of West China Hospital.

Cell Culture

SK-N-SH cells were purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). Dulbecco's modified eagle medium (DMEM, 12100-46; Thermo Fisher Scientific, MA, USA) containing 10% fetal bovine serum was cultured in an incubator at 37°C with 5% CO2 20–22. The specification of carboplatin injection is 10 mL:100 mg (Qilu Pharmaceutical Co., Ltd, Jinan City, Shandong Province; batch no. H20020180). SK-N-SH cells were divided into two groups. The treatment group was injected with 25 μM carboplatin to intervene with cells while the control group was treated with drug solvents. After being treated for 24 and 72 h, respectively, cells were collected for subsequent experimental detection.

Real-Time Polymerase Chain Reaction (PCR)

Real-time polymerase chain reaction (PCR) was used to detect the gene expression level of Ki67 in different groups, and TRIpure Extraction Kit (RP1001; BioTek, Beijing, China) was adopted to extract the total amount of ribonucleic acid (RNA) in each cell group according to instructions. Nanodrop-2000 (Thermo Fisher Scientific, MA, USA) was used to detect the RNA concentration in each group. Reverse transcription was carried out using real-time PCR (Exicycler 96; BIONEER, Republic of Korea) and Super M-MLV reverse (PR6502; BioTek). Then, real-time PCR was done by using 2× power Taq PCR mastermix (PR1702; BioTek) and SYBR Green I (SY1020; Solarbio, Beijing, China). Based on the internal parameter of β-actin, the relative messenger RNA (mRNA) expression level of Ki67 was calculated through the formula 2−ΔΔCt 23. The primer sequence is shown in Table 1, which was synthesized by Sangon Biotech Co., Ltd. (Shanghai, China).

Table 1.

Primer Sequence.

Primer name Forward primer (5′–3′) Reserve primer (5′–3′)
Ki67 GCAGGACTTCACTTGCTTCC TCATTTGCGTTTGTTTCAC
Open in a new tab

Western Blot

The cells were collected and lysed on ice for 5 min with radio immunoprecipitation assay (RIPA) lysis buffer (P0100; Solarbio) containing 1 mM phenylmethane, then centrifuged at 12,000 rpm, 4°C for 10 min, and from the separated supernatant protein was extracted. BCA Protein Assay Kit (PC0020; Solarbio) was used for protein quantification. According to the experimental process of western blot (WB), the protein was separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to polyvinylidene fluoride (PVDF) membrane (IPVH00010; Millipore, MA, USA). It was sealed with 5% skimmed milk. After adding Ki67 antibody (1:500 dilution; WL01384a; Wanleibio, Shenyang), it was incubated overnight at 4°C. After cleansing with tris buffered saline tween (TBST), it was incubated with horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG (1:3000 dilution; SE134; Solarbio). So it was the same process with the internal parameter β-actin. Finally, the electrochemiluminescence (ECL) luminescent liquid (PE0010; Solarbio) was added and exposed in a dark room. The film was scanned and the optical density of the target strip was analyzed by gel image processing system (Gel-Pro-Analyzer, State of California, USA).

Immunocytochemistry

As the cells were collected, cells grown on cover slips were prepared and fixed with 4% paraformaldehyde solution. Formaldehyde was removed and 0.1% Triton X-100 was added for incubation for 20 min. After removal, 0.01 M PBS was added and soaked for 5 min three times. Then, phosphate buffer saline (PBS) was removed and serum was added and sealed for 15 min. After the serum was removed, Ki67 primary antibody diluted with PBS at 1:200 (1:300 dilution; WL0280a; Wanleibio) was added for overnight incubation at 4°C. Then, the primary antibody was removed, 0.01 M PBS was added to them, and soaked for 5 min three times.

Afterwards, PBS was discarded; PBS was dripped to dilute HRP-labeled goat anti-rabbit secondary antibody 100 times (1:100 dilution; WLA023a; Wanleibio) until it fully covered the cells. Then the cells were incubated at 37°C for 60 min. After removing the secondary antibody, the cells were soaked in 0.01 M PBS for 5 min three times. Next, PBS was removed and diaminobezidin (DAB) was added for coloration; then hematoxylin was used for restaining. The staining effect was observed and photographed under a microscope.

Hematoxylin–Eosin (HE) Staining

Cells grown on cover slips were prepared, fixed with 4% paraformaldehyde solution for 15 min, and then soaked in distilled water for 5 min three times. Hematoxylin was added and the cells soaked in it for 5 min before being soaked in distilled water for 5 min. Next, they were allowed to stay in 1% hydrochloric acid alcohol for 3 s. After cleansing with distilled water, eosin dye solution was added to them and soaked for 3 min. After eosin staining, 75%, 85%, and 95% concentration levels of ethanol were added in turn, each for 2 min. The staining effect was observed and photographed under the microscope.

Colony Formation Assay

SK-N-SH cells were cultured to a density of about 90% by trypsin enzyme–digesting technique and centrifuged at 1000 rpm for 5 min to collect the cell precipitation. The supernatant was added into the complete medium, and cells were then resuspended. The cells were inoculated according to experimental grouping. The cells in the treatment group were treated with 25 μM carboplatin injection and collected after 24 and 72 h, respectively. The cells of each group were inoculated in the culture dish, each dish inoculated with 400 cells, and the culture dish was cultured at 37°C and 5% CO2. It took about 2 weeks to form clones that could be seen by naked eyes, and then they could be fixed. They were washed with PBS twice and fixed with 4% paraformaldehyde at room temperature for 20 min. Then they were washed with PBS twice, and Richter’s compound dye was used for dying for 5 min. Then, they were washed with water three times before scanning. Under the microscope, the cell mass made of 50 or more cells is the number of clones. Clone formation rate = (number of clones/number of inoculated cells) × 100%24.

Cytotoxicity Tests for Carboplatin on SK-N-SH cells

The cytotoxicity of carboplatin was checked by AlamarBlue viability test which is especially important for the protection of functional effects. The number of living cells was determined indirectly by determining the mitochondrial metabolic activity of the cells under this test. The cells were seeded into duplicate wells of a 48-well plate techno plastic products (TPP) at a density of 1500 cells/mL and precultured under standard conditions (5% CO2, 37°C) for 3 days. Subsequently, cells were treated with 25 μM carboplatin for 24 and 72 h, respectively. Then the cells in each well were seeded with 360 µL medium with 10% AlamarBlue and grown at 37°C under 5% CO2 for 4 h. For control, AlamarBlue was added to untreated cells as well as to medium without cells. The absorbance at 570 and 600 nm were measured by microplate photometer. The viability of the cells was then calculated by using the formula in a previous study25. Viability of the cells=(ODtreated—ODblank/ODcontrol—ODblank)×100%.

Statistical Analysis

All data are expressed as mean ± standard deviation. SPSS 20.0 and GraphPad Prism 8.0 were used for statistical analysis and mapping. T-test was conducted by means of one-way analysis of variance (ANOVA) and multiway ANOVA. When the value of P is less than 0.05, it is considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001).

Results

The Gene Expression Level of Ki67 in the Treatment Group Was Lower Than That in the Control Group

A real-time PRC experiment was carried out in order to study the gene expression of Ki67 in SK-N-SH cells treated with carboplatin injection. The results showed that the gene expression level of Ki67 decreased significantly after being treated for 24 h, and the inhibition effect of Ki67 gene grew more obvious after being treated for 72 h with a highly significant difference; as the action time of carboplatin injection prolonged, the gene expression level of Ki67 in 72 h was much lower than that in 24 h with a highly significant difference (Fig. 1).

Fig. 1.

Fig. 1.

Open in a new tab

The gene expression of Ki67 in different treated cells. There was a significant difference between control-24 and CBP-24 (**P < 0.01); CBP-72 has a highly significant difference from control-72 and CBP-24 (**P < 0.001). CBP: carboplatin.

The Protein Expression of Ki67 in the Treatment Group Was Lower Than That in the Control Group

In order to better clarify the effect of carboplatin injection on the protein expression of Ki67 in cells, WB was used to detect the protein expression level. The results showed that the protein expression level decreased significantly after the treatment of carboplatin injection, and the longer it acted on the protein, the more obvious the effect was, and the more significant the difference would be (Fig. 2A, B).

Fig. 2.

Fig. 2.

Open in a new tab

The effect of different treatments on the expression of Ki67 protein. The expression level of the control group and the treatment group at the same time point and the expression level of CBP-24 and CBP-27 both had a highly significant difference (***P < 0.001). CBP: carboplatin.

ICC Results Showed That the Protein Expression of Ki67 in the Treatment Group Was Lower Than That in the Control Group, and HE Results Showed That the Drug Could Promote Cell Necrosis and Apoptosis

After cells were injected with carboplatin, cells grown on cover slips were prepared. ICC and HE staining were used to observe the protein expression of Ki67 and the morphological changes of the cells. By analyzing the positive percentage of cells in ICC results, it was found that the protein expression of Ki67 in the treatment group was significantly lower than that in the control group and the difference was highly significant (as shown in Fig. 3A). The results of HE staining showed that the cells in control-24 were the same in form and size, while some cells in the carboplatin (CBP)-24 were necrotic or even apoptotic; the cells in control-72 had a high density in a same form, and there were more necrotic cells in the treatment group than in the control group. The necrotic cells are pointed out with green arrows in Figure 3B.

Fig. 3.

Fig. 3.

Open in a new tab

Pathological results after the treatment of SK-N-SH cells with carboplatin injection. (A) The ICC results showed that there was a highly significant difference in the expression of Ki67 between the treatment group and the control group (***P < 0.001); (B) after being injected with carboplatin, the cell apoptosis and necrosis were significantly higher than those of the control group. CBP: carboplatin.

Carboplatin Injection Reduces the Clone Formation Ability of Cells

After treating SK-N-SH cells with different methods, clone formation assay was used to detect the proliferation ability of the cells. The results showed that after being treated for 24 and 72 h, carboplatin injection inhibited and weakened the proliferation of cells. Statistical analysis of the results showed a significant difference, and the effect of 72-h treatment was more obvious than that of 24-h treatment (Fig. 4A, B).

Fig. 4.

Fig. 4.

Open in a new tab

The effect of carboplatin injection on the proliferation of SK-N-SH cells. (A) Pictures of cloning formation assay; (B) There was a significant difference between control-24 and CBP-24 and between CBP-24 and CBP-72 (*P < 0.05); there was a significant difference between CBP-72 and control-72 (**P < 0.01). CBP: carboplatin.

Cytotoxicity Tests for Carboplatin on SK-N-SH Cells

It was demonstrated by the AlamarBlue assay that carboplatin at a concentration of 25 μM displayed no cytotoxicity on SK-N-SH cells after 24 and 72 h incubation (Fig. 5).

Fig. 5.

Fig. 5.

Open in a new tab

AlamarBlue assay of Carboplatin on SK-N-SH cell.

Discussion

In this study, a certain concentration of carboplatin injection was used to intervene with human neuroblastoma SK-N-SH cells. The results in all these aspects showed that carboplatin injection had a significant inhibitory effect on neuroblastoma SK-N-SH. Literature review found that carboplatin injection also plays a similar role in inhibiting other tumors. It can inhibit the proliferation of nonsmall cell lung cancer and facilitate its apoptosis14. In the treatment of retinoblastoma (RB), carboplatin injection also plays a particularly inhibitory role. Similar to RB, neuroblastoma SK-N-SH is also a common disease in children, most of whom are under 3 years, and it has a family genetic tendency. RB is a common malignant tumor in infants and young children, but rarely seen in adults. Carboplatin injection plays an important role in curing RB, saving children’s eyes and reducing infant mortality26.

At present, Ki67 gene is a relatively positive cell proliferation marker. Ki67 was found by Gerdes27 et al. in 1983. Since then it has been proved that Ki67 gene is closely related to cell proliferation and tumor treatment, and it has gradually become a common indicator to judge the degree of malignancy and the prognosis of tumors. In cell cycle, it exists in all other phases as an essential part of cell cycle regulation except for G0 phase. It has been reported that Ki67 is strongly correlated to urinary system tumors. Kamai28 and Korkolopoulou et al.29 after observing the relationship between Ki67 and the malignant degree of bladder cancer came to believe that Ki67 gene played a significant role in tumor screening. By studying the relationship between Ki67 and renal cancer, Pich and Deriese found that the grading of tumors was positively related to the expression of Ki67-positive cells, and that the proliferation index of Ki67 was closely related to the prognosis of renal cancer. In addition, there is plenty of literature showing that Ki67 is related to breast cancer, rectal cancer, pancreatic neuroendocrine tumors, and so on. Deriese and Crabtree30 et al. studied the relationship between Ki67 and renal cancer tissues and found that the degree of tumor grade was positively correlated with the expression of Ki67-positive cells, and the proliferation index of Ki67 was closely related to the prognosis of renal cancer. In addition, there is a large amount of literature showing that Ki67 is related to breast cancer31–33, rectal cancer34, and pancreatic neuroendocrine tumor35.

In this study, it is found that the mRNA and protein expression levels of Ki67 were decreased after the cells were treated with carboplatin injection, both of them being significantly different. Besides, the longer carboplatin injection acted on cells, the more obvious the effect would become. Moreover, clone formation assay also showed that the proliferation ability of the cells injected with carboplatin was significantly weakened, which is of statistical significance compared with that of the control group. By comparing 72 and 24 h, we can clearly see the time dependence of neuroblastoma SK-N-SH cells on the drug effect. It is believed that the effect of carboplatin will be more obvious as the time increases.

It is speculated that after cells were injected with carboplatin, it is Ki67 that played the role of medium, and then regulated the expression of intracellular related pathway proteins, thus leading to functional changes in cells and inhibiting neuroblastoma SK-N-SH. In the follow-up study, effort would be made to further explore the involved signaling pathways and the mechanism by which carboplatin injection played the role of inhibiting tumors. It is believed that with the deepening of research, the action mechanism will be better clarified and play a greater role in the follow-up clinical application.

Footnotes

Ethical Approval: The study was approved by the Institutional Ethics Committee of West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Statement of Human and Animal Rights: This article does not contain any studies with human or animal subjects.

Statement of Informed Consent: There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The author(s) received no financial support for the research and/or authorship of this article.

References

  • 1. Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma. Cell Tissue Res. 2018;372(2):211–221. [DOI] [PubMed] [Google Scholar]
  • 2. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–2211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Nishikawa S, Noguchi H, Tokumitsu T, Ohno A, Moriguchi-Goto S, Maekawa K, Asada Y, Moritake H, Kinoshita M, Yamada A, Takamura K, et al. Diagnosis of pediatric neuroblastoma by urine cytology: a case report. Diagn Cytopathol. 2018;46(3):280–283. [DOI] [PubMed] [Google Scholar]
  • 4. Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, et al. Management of Neuroblastoma: ICMR Consensus Document. Indian J Pediatr. 2017;84(6):446–455. [DOI] [PubMed] [Google Scholar]
  • 5. Kiyonari S, Kadomatsu K. Neuroblastoma models for insights into tumorigenesis and new therapies. Expert Opin Drug Discov. 2015;10(1):53–62. [DOI] [PubMed] [Google Scholar]
  • 6. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003;4(8):472–480. [DOI] [PubMed] [Google Scholar]
  • 7. Matthay KK. Neuroblastoma: biology and therapy. Oncology (Williston Park). 1997;11(12):1857–1875. [PubMed] [Google Scholar]
  • 8. Tonini GP. Growth, progression and chromosome instability of Neuroblastoma: a new scenario of tumorigenesis?. BMC Cancer. 2017;17(1):20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Maxwell EA, Phillips H, Schaeffer DJ, Fan TM. In vitro chemosensitivity of feline injection site-associated sarcoma cell lines to carboplatin. Vet Surg. 2018;47(2):219–226. [DOI] [PubMed] [Google Scholar]
  • 10. Zhu X, Xu J, Cai H, Lang J. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model. J Obstet Gynaecol Res. 2018;44(2):303–311. [DOI] [PubMed] [Google Scholar]
  • 11. Pochop P, Darsova D, Uhlik J, Lestak J, Kukacka J, Kodetova D, Klapkova E, Malis J, Vajner L. Retinal toxicity after repeated intravitreal carboplatin injection into rabbit eyes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(4):552–556. [DOI] [PubMed] [Google Scholar]
  • 12. Shi M, Anantha M, Wehbe M, Bally MB, Fortin D, Roy LO, Charest G, Richer M, Paquette B, Sanche L. Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats. J Nanobiotechnology. 2018;16(1):77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Ikeda T, Kisu I, Sakamoto Y. [Safety evaluation of paclitaxel injection NK in tri-weekly administration of paclitaxel plus carboplatin (TC therapy) for gynecological cancers [in Japanese]. Gan To Kagaku Ryoho. 2017;44(11):1007–1010. [PubMed] [Google Scholar]
  • 14. Saranya K, Sreejith K, Ajaykumar Comparison of quality of life of patients on treatment with cisplatin and gemcitabine, carboplatin and gemcitabine, carboplatin and paclitaxel, carboplatin and pemetrexed for non-small cell lung cancer. J Oncol Pharm Pract. 2019;25(8):1853–1859. [DOI] [PubMed] [Google Scholar]
  • 15. Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms [published correction appears in Virchows Arch. 2017 Dec 26]. Virchows Arch. 2018;472(3):341–349. [DOI] [PubMed] [Google Scholar]
  • 16. Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566–1572. [DOI] [PubMed] [Google Scholar]
  • 17. Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49(2):166–171. [DOI] [PubMed] [Google Scholar]
  • 18. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174–183. [DOI] [PubMed] [Google Scholar]
  • 19. Kanthiya K, Khunnarong J, Tangjitgamol S, Puripat N, Tanvanich S. Expression of the p16 and Ki67 in cervical squamous intraepithelial lesions and cancer. Asian Pac J Cancer Prev. 2016;17(7):3201–3206. [PubMed] [Google Scholar]
  • 20. Han Z, Li B, Wang J, Zhang X, Li Z, Dai L, Cao M, Jiang J. Norcantharidin inhibits SK-N-SH neuroblastoma cell growth by induction of autophagy and apoptosis. Technol Cancer Res Treat. 2017;16(1):33–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Bhanothu V, Kondapi AK. Status of topoisomerase-2β protein in all-trans retinoic acid-treated human neuroblastoma (SK-N-SH) cells. J Cell Biochem. 2019;120(4):5169–5182. [DOI] [PubMed] [Google Scholar]
  • 22. Singh C, Roy-Chowdhuri S. Quantitative real-time PCR: recent advances. Methods Mol Biol. 2016;1392:161–176. [DOI] [PubMed] [Google Scholar]
  • 23. Maxwell P, Salto-Tellez M. Validation of immunocytochemistry as a morphomolecular technique. Cancer Cytopathol. 2016;124(8):540–545. [DOI] [PubMed] [Google Scholar]
  • 24. Masato I, Richard L. Pre-B-cell colony formation assay. Methods Mol Biol. 2005. ; 292:279–284. [DOI] [PubMed] [Google Scholar]
  • 25. Yin Q, Fischer L, Noethling C, Schaefer WR. In vitro-assessment of putative antiprogestin activities of phytochemicals and synthetic UV absorbers in human endometrial Ishikawa cells. Gynecol Endocrinol. 2015;31(7):578–581. [DOI] [PubMed] [Google Scholar]
  • 26. Said AMA, Aly MG, Rashed HO, Rady AM. Safety and efficacy of posterior sub-Tenon’s carboplatin injection versus intravitreal melphalan therapy in the management of retinoblastoma with secondary vitreous seeds. Int J Ophthalmol. 2018;11(3):445–455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138(4):867–873. [PMC free article] [PubMed] [Google Scholar]
  • 28. Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. 2001;85(3):471]. Br J Cancer. 2001;84(9):1242–1251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol. 2000;31(6):751–760. [DOI] [PubMed] [Google Scholar]
  • 30. de Riese WT, Crabtree WN, Allhoff EP, Werner M, Liedke S, Lenis G, Atzpodien J, Kirchner H. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol. 1993;11(9):1804–1808. [DOI] [PubMed] [Google Scholar]
  • 31. Wang YX, Wang YY, Yang CG, Bu H, Yang WT, Wang L, Xu WM, Zhao XL, Zhao WX, Li L, Song SL, et al. An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer. Breast. 2020;49:225–232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Mohammed AA. Quantitative assessment of Ki67 expression in correlation with various breast cancer characteristics and survival rate; cross sectional study. Ann Med Surg (Lond). 2019;48:129–134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Silva LRD, Vargas RF, Shinzato JY, Derchain SFM, Ramalho S, Zeferino LC. Association of menopausal status, expression of progesterone receptor and Ki67 to the clinical response to neoadjuvant chemotherapy in luminal breast cancer. Rev Bras Ginecol Obstet. 2019;41(12):710–717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Imaizumi K, Suzuki T, Kojima M, Shimomura M, Sakuyama N, Tsukada Y, Sasaki T, Nishizawa Y, Taketomi A, Ito M, Nakatsura T. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. Cancer Sci. 2020;111(1):23–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Nieveen van Dijkum EJM. ASO Author reflections: pancreatic neuroendocrine tumor recurrence and survival predicted by Ki67. Ann Surg Oncol. 2019;26(Suppl 3):531–532. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cell Transplantation are provided here courtesy of SAGE Publications

RESOURCES